For centuries, a spinal cord injury, stroke, or severe neurological condition meant a permanent transition to a wheelchair. While wheelchairs offer crucial mobility, they do not replace the physiological and psychological benefits of standing up and walking on two feet. Sitting all day causes secondary health complications, such as poor circulation, loss of bone density, joint stiffness, and chronic pain. The medical world has long searched for a way to help paralyzed individuals walk again, but the solution remained out of reach for most patients due to heavy, expensive, and overly complex machinery.
A new wave of robotic technology is fundamentally changing this landscape. At the center of this shift is Alfons Carnicero Carmona, an engineer and entrepreneur from Barcelona, Spain. As the co-founder and CEO of ABLE Human Motion, Carnicero is leading a team that builds lightweight, accessible, and smart medical exoskeletons. By combining advanced robotics with intuitive control systems, his work bridges the gap between high-tech machinery and real human needs, aiming to make robotic rehabilitation a standard option for clinical environments and home use worldwide.
The Cost and Weight of Standing Up
The global healthcare market has seen various robotic gait trainers and lower-limb exoskeletons over the past two decades. However, traditional designs suffer from significant structural flaws that limit their practical use. Standard medical exoskeletons are heavy, often weighing between 20 and 25 kilograms (44 to 55 pounds). This extreme weight requires a large amount of power, creating a cycle where larger batteries and bulkier motors are needed just to support the machine itself.
Furthermore, these traditional units are notoriously difficult to operate. They require extensive setup times, complex programming, and a high level of physical assistance from multiple clinical therapists just to get a patient securely strapped in.
The biggest barrier, however, remains the economic cost. Most medical-grade exoskeletons cost around €100,000 (roughly $110,000 USD) per unit. This pricing makes them luxury assets that only elite private clinics and heavily funded research institutions can afford. The vast majority of standard rehabilitation centers, local hospitals, and individual patients find this technology completely inaccessible. As a result, millions of people who could benefit from intensive robotic gait therapy are left without options due to high costs and design inefficiencies.
Bridging Engineering and Medicine
Alfons Carnicero Carmona stepped into this environment with a distinct academic and professional background. He earned a Master’s degree in Industrial Engineering with a specialized major in Biomedical Engineering from the Universitat Politècnica de Catalunya (UPC) in Barcelona. Believing that technical training needs strong business acumen to make a real-world impact, Carnicero expanded his education with specialized entrepreneurship and business courses at prominent institutions, including Cambridge Judge Business School, EADA, and ISDI.
Before launching his own enterprise, Carnicero worked within both the manufacturing and clinical sides of healthcare technology. He gained experience at Implantcast, a major joint implants manufacturer, where he learned the strict quality controls and engineering precision required for permanent orthopedic devices.
He then worked closely with the Institut Guttmann, a highly respected neurorehabilitation hospital in Spain. This clinical exposure allowed Carnicero to observe patients with spinal cord injuries and stroke survivors during their daily physical therapy sessions. He saw firsthand the immense physical effort required from therapists and the frustrations of patients using bulky, outdated, or unavailable equipment. These experiences convinced him that the industry needed a lighter, cheaper, and more natural solution.
A Vision Born on the Hospital Floor
Carnicero’s motivation to build a medical robotics company did not come from an abstract interest in machinery, but from watching clinicians and patients interact. At the neurorehabilitation hospital, he noticed that while therapists were incredibly dedicated, traditional manual gait training, physically moving a patient’s paralyzed legs to simulate walking, was exhausting and lacked precision. The existing robotic alternatives were so massive that patients felt trapped inside a machine rather than empowered to walk.
He realized that true innovation meant putting the user in control. A patient should feel the machine responding to their own physical intent, rather than just being pushed along by a rigid program. Carnicero focused on a clear goal: to design a wearable device that mimics natural human movement, weighs less than half of traditional options, and sells at a fraction of the market cost. This focus on accessibility became the core philosophy behind his entrepreneurial journey.
From University Research to a Growing Enterprise
In October 2018, Carnicero co-founded ABLE Human Motion alongside his university engineering classmate Alex Garcia and their mechanical engineering professor, Dr. Josep Maria Font-Llagunes. The foundational concepts for the company came from over eight years of academic research conducted at the BIOMEC Assessment Lab of the Universitat Politècnica de Catalunya. Carnicero and his co-founders took these core laboratory concepts and focused on turning them into a viable commercial medical device.
Operating out of Barcelona, the company grew from a small university spin-out into a structured organization with a highly specialized team. To build a truly useful device, the engineering team worked closely with clinical experts, physical therapists, and patients, conducting over 150 interviews and usability sessions during the early design phases.
The resulting product, the ABLE Exoskeleton, features key technological shifts:
- Electric Actuators: Compact, highly efficient motors flex and extend the knee joint to replicate a natural walking stride.
- Inertial Sensors: Built-in sensors detect small changes in the patient’s center of mass, recognizing when they want to take a step forward and executing the movement smoothly.
- Smart Software: Proprietary algorithms adjust assistance levels based on the patient’s real-time performance and unique motor needs.
Navigating Regulations and Supply Chains
Building a medical device company presents distinct challenges compared to software or consumer hardware startups. The regulatory framework for medical technology is strict, requiring lengthy clinical trials, detailed documentation, and extensive safety verification. Carnicero successfully guided his young company through the complicated process of obtaining a CE Mark under Europe’s strict Medical Device Regulation (MDR). This certification formally approved the device for spinal cord injury rehabilitation in clinical settings.
Financing these long development cycles required a careful mix of capital. Under Carnicero’s leadership, ABLE Human Motion raised over €5.5 million through equity investment rounds, accelerator programs, and competitive public grants. The company received crucial support from European Union initiatives, including the prestigious EIC Accelerator and the EIT Health program. This funding allowed them to run extensive clinical trials in leading neurorehabilitation centers across Spain and Germany, proving the device’s safety, efficiency, and therapeutic value.
More recently, the global robotics industry has faced shifting macroeconomic pressures, including changes in international trade and rising component costs. For a company relying on specialized materials and electronic actuators, managing supply chain stability while keeping production costs low is an ongoing challenge. Carnicero’s team addressed this by focusing on regional manufacturing partnerships and maximizing design efficiency to avoid relying on expensive, tariff-heavy components.
Achieving Recognition and Defining the Market
The medical and technology communities quickly noted Carnicero’s impact on rehabilitation engineering. In 2022, MIT Technology Review named him one of its “Innovators Under 35 Europe,” pointing to his team’s success in creating a lighter, more accessible exoskeleton. He was also recognized as a “Joven Relevante” (Relevant Youth) by the Círculo Ecuestre in Barcelona, highlighting his status as a prominent young entrepreneur in the region.
Carnicero’s expertise extends beyond his own company. He serves on the Steering Committee of the International Industry Society for Advanced Rehabilitation Technology (IISART). In this role, he helps establish global standards for rehabilitation robotics, promotes data sharing between clinical centers, and advocates for broader insurance coverage for advanced medical technologies.
Empathy and Precision in Leadership
As an executive, Carnicero combines an engineer’s focus on data with a healthcare provider’s empathy. He encourages an organizational culture focused on purposeful innovation, often reminding his team that they are building technology to “turn disability into ability.” This clear sense of mission helps attract top-tier engineering and clinical talent who want their daily work to have a clear social impact.
His management style is highly collaborative and iterative. Rather than keeping development inside a closed lab, Carnicero ensures that engineers, marketing specialists, and clinical application managers work together daily. He also maintains an open loop with the medical community, ensuring that feedback from a therapist in a clinic is quickly integrated into software updates and hardware revisions.
Moving Toward Home Rehabilitation
The future of ABLE Human Motion is focused on expanding commercial reach and broadening the product line. Following its initial approval for spinal cord injuries, the device secured additional regulatory CE certifications under the MDR to expand treatment capabilities to Multiple Sclerosis (MS) and other neuromuscular disorders. Having successfully deployed units across major public and private hospitals in Europe, the company is actively establishing distribution networks in North America and the Asia-Pacific region.
The company’s long-term vision looks beyond the clinic walls. While the current model is optimized for therapists guiding patients in a hospital setting, Carnicero’s ultimate goal is to develop an exoskeleton certified for personal use at home and in daily life. A home-use device would allow individuals with spinal cord injuries or stroke survivors to continue their recovery independently, significantly lower long-term healthcare costs, and enjoy greater personal freedom. By continuing to reduce weight, lower costs, and improve smart control systems, Carnicero and his team are making robotic mobility a realistic option for people worldwide.
